Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Adaptimmune Therapeutics Q4 EPS $(0.04) Beats $(0.10) Estimate, Sales $231.00K May Not Be Comparable To $20.47M Estimate

Author: Benzinga Newsdesk | March 06, 2024 08:13am
Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.10) by 60 percent. This is a 33.33 percent decrease over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $231.00 thousand which missed the analyst consensus estimate of $20.47 million by 98.87 percent. This is a 97.91 percent decrease over sales of $11.03 million the same period last year.

Posted In: ADAP


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist